We recently had a conference with over 100 journalists, scientists, and policymakers in attendance that looked at the media?s emphasis on the risks of medicines at the expense of a more balanced approach to coverage.
CMPI is now conducting research as to whether or not consumers will actually benefit from follow-on biologics compared to increased investment in new biologics. We are also holding a conference in Washington about alternatives to proposals to restrict patient and physician access to drugs as a way to limit drug risk contained in Institute of Medicine report and congressional FDA proposals. Our approach would rely on biomarkers based trials and more advanced health information technology in the post market. This latter activity is being conducted in cooperation with patient groups and the Critical Path Institute.